The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome
10.3760/cma.j.issn.0578-1426.2019.12.008
- VernacularTitle: 低剂量地西他滨皮下注射联合三氧化二砷诱导治疗11例中高危骨髓增生异常综合征的安全性与疗效分析
- Author:
Hao AI
1
;
Xudong WEI
;
Qingsong YIN
;
Ruihua MI
;
Lin CHEN
;
Qian WANG
;
Yongping SONG
Author Information
1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
- Publication Type:Case Reports
- Keywords:
Myelodysplastic syndromes;
Decitabine;
Low dose;
Injections, subcutaneous;
Arsenic trioxide
- From:
Chinese Journal of Internal Medicine
2019;58(12):908-910
- CountryChina
- Language:Chinese
-
Abstract:
To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS). Three of the total 11 MDS patients achieved complete remission (CR) and 6 achieved hematological improvement (HI), 1 stable disease (SD), and 1 progressive disease (PD). One patient was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time was 413(90-1 275) d. Nine patients were still alive. Low dose subcutaneous decitabine combined with arsenic trioxide can be an alternative regimen for intermediate or high-risk MDS patients.
